Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:GHRS NASDAQ:LENZ NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$11.20-0.9%$9.72$4.93▼$14.44$965.21M0.81.16 million shs866,336 shsGHRSGH Research$13.74-4.3%$13.82$6.00▼$20.50$747.12M0.97350,928 shs273,409 shsLENZLENZ Therapeutics$29.96+0.6%$31.03$16.53▼$38.93$849.10M0.42278,602 shs1.57 million shsSOPHSOPHiA GENETICS$3.16+1.0%$3.19$2.58▼$4.92$208.73M134,464 shs24,042 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-0.88%-7.67%+5.96%+19.66%+64.83%GHRSGH Research-4.32%-5.24%-8.58%+20.63%+10.81%LENZLENZ Therapeutics+0.64%-5.25%-3.23%+1.49%+20.66%SOPHSOPHiA GENETICS+0.96%-12.22%+3.95%+4.29%-28.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.6596 of 5 stars3.50.00.04.73.10.80.6GHRSGH Research2.2656 of 5 stars3.52.00.00.02.42.50.0LENZLENZ Therapeutics1.5155 of 5 stars3.60.00.00.03.10.80.0SOPHSOPHiA GENETICS1.4111 of 5 stars3.33.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.00Buy$44.00292.86% UpsideGHRSGH Research 3.00Buy$32.00132.90% UpsideLENZLENZ Therapeutics 3.17Buy$49.6065.55% UpsideSOPHSOPHiA GENETICS 2.67Moderate Buy$7.00121.52% UpsideCurrent Analyst Ratings BreakdownLatest SOPH, AVXL, GHRS, and LENZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $49.007/31/2025LENZLENZ TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$39.00 ➝ $40.007/28/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $48.006/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$39.006/4/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.005/13/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025GHRSGH ResearchGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $29.005/9/2025GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AGHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/ALENZLENZ TherapeuticsN/AN/AN/AN/A$7.24 per shareN/ASOPHSOPHiA GENETICS$65.17M3.23N/AN/A$1.48 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-40.93%-36.38%8/5/2025 (Estimated)GHRSGH Research-$38.96M-$0.79N/AN/AN/AN/A-19.20%-18.40%9/2/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%8/13/2025 (Estimated)SOPHSOPHiA GENETICS-$62.49M-$1.00N/AN/AN/A-98.51%-63.47%-40.06%8/5/2025 (Estimated)Latest SOPH, AVXL, GHRS, and LENZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025LENZLENZ Therapeutics-$0.62N/AN/AN/AN/AN/A8/5/2025Q3 2025AVXLAnavex Life Sciences-$0.13N/AN/AN/AN/AN/A8/5/2025Q2 2025SOPHSOPHiA GENETICS-$0.25N/AN/AN/A$17.49 millionN/A7/30/2025Q2 2025LENZLENZ Therapeutics-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 million5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/A5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A6.746.74GHRSGH ResearchN/A29.7129.71LENZLENZ TherapeuticsN/A20.5423.09SOPHSOPHiA GENETICS0.163.112.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%GHRSGH Research56.90%LENZLENZ Therapeutics54.32%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%GHRSGH Research41.60%LENZLENZ Therapeutics6.90%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.42 million75.68 millionOptionableGHRSGH Research1052.03 million30.38 millionOptionableLENZLENZ Therapeutics11028.52 million26.20 millionN/ASOPHSOPHiA GENETICS52066.69 million63.43 millionNot OptionableSOPH, AVXL, GHRS, and LENZ HeadlinesRecent News About These CompaniesSOPHiA GENETICS (SOPH) Expected to Announce Quarterly Earnings on TuesdayJuly 29, 2025 | marketbeat.comSOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025July 22, 2025 | prnewswire.comTurning Proof Into Power: Bioz Partners With SOPHiA GENETICS to Enhance Scientific Transparency via Custom IntegrationJuly 15, 2025 | pharmiweb.comPSOPHiA GENETICS (NASDAQ:SOPH) Stock Price Up 8.7% - What's Next?July 8, 2025 | marketbeat.comSophia Genetics launches podcast to decode data- and AI-driven medical innovationJune 27, 2025 | fiercepharma.comFAn end to an era: Supreme Court won't review IVF mixup rulingJune 26, 2025 | israelnationalnews.comIEnough hype about AI in health—let’s talk about resultsJune 12, 2025 | fastcompany.comFM42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and careJune 3, 2025 | zawya.comZM42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, careJune 3, 2025 | msn.comM42, partners launch liquid biopsy testing in UAEJune 3, 2025 | tradearabia.comTThe Multimodal Imperative: How AI-Driven Technology is Driving Impactful ChangesJune 2, 2025 | fiercepharma.comF'An unusual precedent': Baby Sophia's genetic parents demand new Supreme Court hearingMay 28, 2025 | israelnationalnews.comIHigh Court grants custody of IVF baby to adoptive, not biological parentsMay 12, 2025 | msn.comSOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2025 | uk.finance.yahoo.comSupreme Court: IVF mixup baby to remain with birth parentsMay 12, 2025 | israelnationalnews.comISupreme Court rules birth parents of child born in IVF mix-up are legal parentsMay 12, 2025 | msn.comSupreme Court upholds decision to keep IVF child with birth mother following embryo mix-upMay 12, 2025 | msn.comThe Sophia Case: When Parenthood Isn’t Just About GeneticsMay 10, 2025 | blogs.timesofisrael.comBSOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comSophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ...May 7, 2025 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Chipotle: Too Spicy for Smart Money to Resist After Stock SplitBy Jeffrey Neal Johnson | July 11, 2025View Chipotle: Too Spicy for Smart Money to Resist After Stock SplitSOPH, AVXL, GHRS, and LENZ Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$11.20 -0.10 (-0.88%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.15 -0.05 (-0.45%) As of 08/1/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.GH Research NASDAQ:GHRS$13.74 -0.62 (-4.32%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.72 -0.03 (-0.18%) As of 08/1/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.LENZ Therapeutics NASDAQ:LENZ$29.96 +0.19 (+0.64%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$30.10 +0.14 (+0.47%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.SOPHiA GENETICS NASDAQ:SOPH$3.16 +0.03 (+0.96%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.14 -0.02 (-0.47%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
